Biodexa Pharma Gets European CTA Approval for Phase 3 Serenta Trial
Ticker: BDRX · Form: 6-K · Filed: Nov 3, 2025 · CIK: 1643918
| Field | Detail |
|---|---|
| Company | Biodexa Pharmaceuticals PLC (BDRX) |
| Form Type | 6-K |
| Filed Date | Nov 3, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: clinical-trial, regulatory-approval, drug-development
TL;DR
Biodexa got the green light in Europe for its Phase 3 Serenta trial. Big step forward.
AI Summary
Biodexa Pharmaceuticals PLC announced on November 3, 2025, that it has received approval for its Clinical Trial Application (CTA) in Europe for the Phase 3 Serenta clinical trial. This approval allows the company to proceed with its pivotal trial for Serenta, a key step in its drug development process.
Why It Matters
This approval is a significant milestone for Biodexa, enabling them to advance their lead drug candidate into late-stage clinical trials, bringing it closer to potential market approval.
Risk Assessment
Risk Level: medium — Advancing to Phase 3 trials involves significant costs and inherent risks of clinical trial failure, which could impact the company's future.
Key Players & Entities
- Biodexa Pharmaceuticals PLC (company) — Registrant
- Serenta (drug) — Lead drug candidate
FAQ
What is the specific indication for the Phase 3 Serenta clinical trial?
The filing does not specify the indication for the Phase 3 Serenta clinical trial.
When is the expected start date for the Phase 3 Serenta clinical trial?
The filing does not provide an expected start date for the Phase 3 Serenta clinical trial.
Which European countries are included in the CTA approval for the Serenta trial?
The filing states approval in 'Europe' but does not list specific countries.
What is the previous name of Biodexa Pharmaceuticals PLC?
The previous name of Biodexa Pharmaceuticals PLC was Midatech Pharma Plc, with a name change date of June 2, 2015.
What is the primary business of Biodexa Pharmaceuticals PLC?
Biodexa Pharmaceuticals PLC is in the Pharmaceutical Preparations industry (SIC code 2834).
Filing Stats: 510 words · 2 min read · ~2 pages · Grade level 18.6 · Accepted 2025-11-03 08:38:11
Filing Documents
- z10312506k.htm (6-K) — 13KB
- ex99_1.htm (EX-99.1) — 17KB
- 0001214659-25-015739.txt ( ) — 32KB
From the Filing
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2025 Commission File Number 001-37652 Biodexa Pharmaceuticals PLC (Translation of registrant’s name into English) 1 Caspian Point, Caspian Way Cardiff, CF10 4DQ, United Kingdom (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F x Form 40-F ¨ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨ Approval of CTA in Europe for Phase 3 Serenta Clincial Trial On November 3, 2025, Biodexa Pharmaceuticals PLC (the “Company”) announced the approval of a Clinical Trial Application (“CTA”) by the European Medicines Agency (“EMA”) of its pivotal Phase 3 Serenta clinical trial of eRapa in patients with familial adenomatous polyposis (“FAP”). The CTA permits the Phase 3 Serenta clinical trial to proceed in Europe, initially covering sites in Denmark, Germany, the Netherlands and Spain, with Italy expected to be added. The information included under the heading “Approval of CTA in Europe for Phase 3 Serenta Clinical Trial” shall be deemed to be incorporated by reference into the registration forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. Press Release On November 3, 2025, the Company issued a press release regarding the approval of a CTA by the EMA of its pivotal Phase 3 Serenta trial of eRapa in patients with FAP, a copy of which is attached to this Form 6-K as Exhibit 99.1. The information in the attached Exhibit 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing. SUBMITTED HEREWITH Attached to the Registrant’s Form 6-K filing for the month of November 2025 is: Exhibit No. Description 99.1 Press release dated November 3, 2025. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Biodexa Pharmaceuticals PLC Date: November 3, 2025 By: /s/ Stephen Stamp Stephen Stamp Chief Executive Officer and Chief Financial Officer